ReviewCritical reviews in immunology2019
Advances in the Study of CD8+ Regulatory T Cells.
Review in Critical reviews in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Targeting Immune Checkpoint Proteins in Cancer Therapy and the Potential of RNAi-Based Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Two subsets of regulatory CD8iScience · 2025Article
- A narrow T cell receptor repertoire instructs thymic differentiation of MHC class Ib-restricted CD8+ regulatory T cells.The Journal of clinical investigation · 2024Article
- Article
- Renegade T cell clones and autoimmune disease.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications.Frontiers in immunology · 2023Review
- FoxP3Frontiers in immunology · 2022Article
- Targeting natural killer cells to enhance vaccine responses.Trends in pharmacological sciences · 2021Review
- Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Harnessing Tolerogenic Histone Peptide Epitopes From Nucleosomes for Selective Down-Regulation of Pathogenic Autoimmune Response in Lupus (Past, Present, and Future).Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Immune tolerance mediated by CD4+ and CD8+ regulatory T (Treg) cells is important in the control of inflammatory and autoimmune diseases. Although CD4+FoxP3+ Treg cells are well studied, our current knowledge of the biology of CD8+ Treg cells has several critical gaps. A major limitation was our inability to distinguish them from conventional CD8+ T cells. In this regard, we have recently discovered an innate-like PLZF+CD8αα+TCRαβ+ Treg population (CD8αα Treg cells) that is enriched in the liver in naive mice and present in healthy humans. We have demonstrated that these CD8αα Treg cells serve as a feedback regulatory mechanism and target only activated effector T cells. Such feedback regulation allows the progression of an immune defense response yet prevents excessive tissue damage. It is likely that the PLZF transcription program endows the CD8αα Treg cells with the innate features that are important for them to effectively control autoimmune responses by targeting activated T cells in both mice and humans. Additional features of the CD8αα Treg cells include their dependence on IL-15/IL-2Rβ signaling, the expression of NK-inhibitory receptors, and the memory phenotype. Importantly, these cells are expanded following an ongoing immune response and serve as a feedback regulatory mechanism to control activated effector T cells, and hence prevent an excessive immune stimulation. In this review, we will briefly summarize recent important findings related to CD8+ Treg cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.